Capricor Therapeutics Faces Class Action Over Deramiocel Disclosures

The complaint alleges that Capricor executives modified the statistical analysis plan for clinical data without prior FDA agreement before resubmitting its Biologics License Application. This omission allegedly created a false narrative surrounding the drug's path to approval, masking significant risks that the clinical results would fail to provide substantial evidence of effectiveness. Shareholders contend that these actions rendered the company's public statements regarding its business operations materially false and misleading.

Those seeking to serve as lead plaintiff in the case must submit their requests to the court by September 28, 2026. While the firm, led by founding partner Peretz Bronstein, operates on a contingency fee basis, investors are not required to serve as lead plaintiffs to participate in any potential recovery. Further details on the litigation and instructions for joining the class action are available through the firm’s website at bgandg.com/CAPR.